SUFENTANYL
Postoperative Analgesia
IVO JURISICSmall moleculePhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Postoperative Analgesia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Konya Meram State Hospital | Phase 4 | BB |
Meperidine IVO JURISIC | Phase 4 | BB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE IVO JURISIC | Phase 4 | BB |
Amitriptyline Peking University First Hospital | Phase 4 | BB |
Pregabalin Peking University First Hospital | Phase 4 | B |
View all 15 →
Same molecule, other indications
SUFENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →